CN106645762A - 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 - Google Patents
中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 Download PDFInfo
- Publication number
- CN106645762A CN106645762A CN201611228284.5A CN201611228284A CN106645762A CN 106645762 A CN106645762 A CN 106645762A CN 201611228284 A CN201611228284 A CN 201611228284A CN 106645762 A CN106645762 A CN 106645762A
- Authority
- CN
- China
- Prior art keywords
- ngal
- associated lipocalin
- neutrophil gelatinase
- antibody
- detection kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010051335 Lipocalin-2 Proteins 0.000 title claims abstract description 120
- 102000013519 Lipocalin-2 Human genes 0.000 title claims abstract description 120
- 238000001514 detection method Methods 0.000 title claims abstract description 52
- 239000004816 latex Substances 0.000 claims abstract description 37
- 229920000126 latex Polymers 0.000 claims abstract description 37
- 239000002245 particle Substances 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000000126 substance Substances 0.000 claims abstract description 16
- 210000004408 hybridoma Anatomy 0.000 claims description 32
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 15
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- 239000004793 Polystyrene Substances 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- 239000007983 Tris buffer Substances 0.000 claims description 8
- 229920002223 polystyrene Polymers 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 8
- 102000013382 Gelatinases Human genes 0.000 claims description 5
- 108010026132 Gelatinases Proteins 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical group FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 4
- 229940033663 thimerosal Drugs 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 102000019298 Lipocalin Human genes 0.000 claims 2
- 108050006654 Lipocalin Proteins 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 238000004879 turbidimetry Methods 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000012980 RPMI-1640 medium Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000014674 injury Diseases 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 208000009304 Acute Kidney Injury Diseases 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 7
- 208000033626 Renal failure acute Diseases 0.000 description 7
- 201000011040 acute kidney failure Diseases 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000003149 assay kit Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 208000012998 acute renal failure Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003448 neutrophilic effect Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 description 3
- 235000011151 potassium sulphates Nutrition 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 2
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102100026897 Cystatin-C Human genes 0.000 description 1
- 102100028007 Cystatin-SA Human genes 0.000 description 1
- 101710144510 Cysteine proteinase inhibitor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150071461 HAVCR1 gene Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241001282153 Scopelogadus mizolepis Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- -1 benzene Diamidogen Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611228284.5A CN106645762B (zh) | 2016-12-27 | 2016-12-27 | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611228284.5A CN106645762B (zh) | 2016-12-27 | 2016-12-27 | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106645762A true CN106645762A (zh) | 2017-05-10 |
CN106645762B CN106645762B (zh) | 2018-10-30 |
Family
ID=58832726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611228284.5A Active CN106645762B (zh) | 2016-12-27 | 2016-12-27 | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106645762B (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107525938A (zh) * | 2017-08-24 | 2017-12-29 | 菲鹏生物股份有限公司 | 急性肾损伤的检测试剂盒 |
CN107607724A (zh) * | 2017-08-11 | 2018-01-19 | 中山市创艺生化工程有限公司 | 一种用于补体c3测定试剂盒的复合稳定剂及其应用 |
CN107677809A (zh) * | 2017-08-24 | 2018-02-09 | 菲鹏生物股份有限公司 | 急性肾损伤的检测试剂盒 |
CN107991496A (zh) * | 2017-11-29 | 2018-05-04 | 山东诺安爱迪尔生物工程有限公司 | 一种中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
CN108008130A (zh) * | 2017-11-24 | 2018-05-08 | 海格德生物科技(深圳)有限公司 | 基于胶乳增强免疫比浊法测定Lp-PLA2的试剂盒及其制备方法 |
WO2019037044A1 (zh) * | 2017-08-24 | 2019-02-28 | 菲鹏生物股份有限公司 | 急性肾损伤的检测试剂盒 |
WO2019037043A1 (zh) * | 2017-08-24 | 2019-02-28 | 菲鹏生物股份有限公司 | 急性肾损伤的检测试剂盒 |
CN110058015A (zh) * | 2019-04-08 | 2019-07-26 | 深圳优普生物技术有限公司 | 试剂、试剂盒、血小板反应指数的测定方法及应用 |
CN110133276A (zh) * | 2019-04-01 | 2019-08-16 | 芜湖森爱驰生物科技有限公司 | 一种中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
CN113402606A (zh) * | 2020-03-17 | 2021-09-17 | 江苏众红生物工程创药研究院有限公司 | 一种中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒及其临床应用 |
CN116655788A (zh) * | 2022-09-16 | 2023-08-29 | 北京中楷健康科技有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白(ngal)尿液检测试剂盒 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011017682A1 (en) * | 2009-08-07 | 2011-02-10 | Rules-Based Medicine, Inc. | Devices for detecting renal disorders |
CN102253217A (zh) * | 2011-04-07 | 2011-11-23 | 武汉生之源生物科技有限公司 | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
CN102680698A (zh) * | 2011-07-29 | 2012-09-19 | 南京诺尔曼生物技术有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白(ngal)测定试剂盒(胶乳增强免疫比浊法) |
CN103880948A (zh) * | 2013-04-11 | 2014-06-25 | 北京爱必信生物技术有限公司 | 人中性粒细胞明胶酶相关载脂蛋白(ngal)的制备方法 |
CN104198732A (zh) * | 2014-08-28 | 2014-12-10 | 宁波瑞源生物科技有限公司 | 一种中性粒细胞明胶酶相关脂质运载蛋白含量检测试剂盒 |
CN104215769A (zh) * | 2014-08-14 | 2014-12-17 | 上海睿康生物科技有限公司 | 一种乳胶增强免疫比浊法ngal检测试剂盒 |
-
2016
- 2016-12-27 CN CN201611228284.5A patent/CN106645762B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011017682A1 (en) * | 2009-08-07 | 2011-02-10 | Rules-Based Medicine, Inc. | Devices for detecting renal disorders |
CN102253217A (zh) * | 2011-04-07 | 2011-11-23 | 武汉生之源生物科技有限公司 | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
CN102680698A (zh) * | 2011-07-29 | 2012-09-19 | 南京诺尔曼生物技术有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白(ngal)测定试剂盒(胶乳增强免疫比浊法) |
CN103880948A (zh) * | 2013-04-11 | 2014-06-25 | 北京爱必信生物技术有限公司 | 人中性粒细胞明胶酶相关载脂蛋白(ngal)的制备方法 |
CN104215769A (zh) * | 2014-08-14 | 2014-12-17 | 上海睿康生物科技有限公司 | 一种乳胶增强免疫比浊法ngal检测试剂盒 |
CN104198732A (zh) * | 2014-08-28 | 2014-12-10 | 宁波瑞源生物科技有限公司 | 一种中性粒细胞明胶酶相关脂质运载蛋白含量检测试剂盒 |
Non-Patent Citations (1)
Title |
---|
DAIJUN XIANG ET AL.: "Particle-enhanced turbidimetric immunoassay for determination of serum neutrophil gelatinase-associated lipocalin on the Roche Cobas c501 analyzer", 《CLINICAL BIOCHEMISTRY》 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107607724B (zh) * | 2017-08-11 | 2020-04-28 | 中山市创艺生化工程有限公司 | 一种用于补体c3测定试剂盒的复合稳定剂及其应用 |
CN107607724A (zh) * | 2017-08-11 | 2018-01-19 | 中山市创艺生化工程有限公司 | 一种用于补体c3测定试剂盒的复合稳定剂及其应用 |
WO2019037043A1 (zh) * | 2017-08-24 | 2019-02-28 | 菲鹏生物股份有限公司 | 急性肾损伤的检测试剂盒 |
WO2019037044A1 (zh) * | 2017-08-24 | 2019-02-28 | 菲鹏生物股份有限公司 | 急性肾损伤的检测试剂盒 |
CN107525938A (zh) * | 2017-08-24 | 2017-12-29 | 菲鹏生物股份有限公司 | 急性肾损伤的检测试剂盒 |
CN107677809A (zh) * | 2017-08-24 | 2018-02-09 | 菲鹏生物股份有限公司 | 急性肾损伤的检测试剂盒 |
CN108008130A (zh) * | 2017-11-24 | 2018-05-08 | 海格德生物科技(深圳)有限公司 | 基于胶乳增强免疫比浊法测定Lp-PLA2的试剂盒及其制备方法 |
CN107991496A (zh) * | 2017-11-29 | 2018-05-04 | 山东诺安爱迪尔生物工程有限公司 | 一种中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
CN110133276A (zh) * | 2019-04-01 | 2019-08-16 | 芜湖森爱驰生物科技有限公司 | 一种中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
CN110058015A (zh) * | 2019-04-08 | 2019-07-26 | 深圳优普生物技术有限公司 | 试剂、试剂盒、血小板反应指数的测定方法及应用 |
CN113402606A (zh) * | 2020-03-17 | 2021-09-17 | 江苏众红生物工程创药研究院有限公司 | 一种中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒及其临床应用 |
CN113402606B (zh) * | 2020-03-17 | 2023-06-06 | 江苏众红生物工程创药研究院有限公司 | 一种中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒及其临床应用 |
CN116655788A (zh) * | 2022-09-16 | 2023-08-29 | 北京中楷健康科技有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白(ngal)尿液检测试剂盒 |
CN116655788B (zh) * | 2022-09-16 | 2023-10-20 | 北京中楷健康科技有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白(ngal)尿液检测试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN106645762B (zh) | 2018-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106645762B (zh) | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 | |
CN103073642B (zh) | Crp单克隆抗体纳米乳胶微球组合物及制备工艺 | |
CN104977404B (zh) | 抑制类风湿因子干扰的胶乳增强免疫比浊试剂 | |
EP1952154B1 (en) | Turbidimetric immunoassay for assessing human cystatin c | |
RU2595854C2 (ru) | Способ диагностики злокачественной опухоли | |
KR101877457B1 (ko) | 신규 단클론항체 및 d 다이머의 면역학적 측정법 | |
JP5199067B2 (ja) | 免疫凝集反応試薬キット及び抗原の測定方法 | |
JPWO2010064435A1 (ja) | ヒト体液中のシスタチンc測定方法 | |
CN102775473B (zh) | 人中性粒细胞明胶酶相关脂质运载蛋白的b细胞表位肽段及其应用 | |
CN106370855B (zh) | 基于BSaBA信号放大***的绵羊过氧化物氧还酶6双抗夹心ELISA试剂盒 | |
CN105542014A (zh) | Tp重组抗原及其制备方法和应用 | |
CN105277711A (zh) | 一种用于检测he4的酶联免疫试剂盒 | |
WO2018119626A1 (zh) | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 | |
CN104181305A (zh) | 抗人中性粒细胞明胶酶相关脂质运载蛋白抗体及其用途 | |
CN107677809A (zh) | 急性肾损伤的检测试剂盒 | |
CN103468644B (zh) | 产生抗人d-二聚体的单克隆抗体的杂交瘤细胞株及制备方法和应用 | |
CN108570104A (zh) | 重组脂联素抗原、抗体及脂联素纳米胶乳增强免疫比浊法试剂盒 | |
CN113045646B (zh) | 抗新型冠状病毒SARS-CoV-2的抗体 | |
CN101356438A (zh) | 评估人半胱氨酸蛋白酶抑制剂c的浊度测定法免疫测定 | |
WO2005114196A1 (ja) | 間質性膀胱炎の検査方法 | |
CN108624564A (zh) | 抗乙肝表面抗原的单抗隆抗体的制备和筛选 | |
CN107525938A (zh) | 急性肾损伤的检测试剂盒 | |
CN105223356A (zh) | Gpi胶乳增强免疫比浊法体外定量测定诊断试剂盒 | |
CN105203770B (zh) | Stim1蛋白在相关疾病风险诊断中的应用 | |
CN106771216B (zh) | 提高免疫试剂检测特异性的方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Ruijing Inventor after: Liu Junpeng Inventor after: Liu Chunyan Inventor after: Zhong Dongmei Inventor after: Meng Yuan Inventor after: Wei Zhongjie Inventor before: Li Ruijing Inventor before: Liu Junpeng Inventor before: Liu Chunyan Inventor before: Zhong Dongmei Inventor before: Meng Yuan Inventor before: Wei Zhongjie |